Phase II study of mitomycin C and vinblastine in women with advanced breast cancer refractory to standard cytotoxic therapy

J. M. Denefrio, D. W. East, M. B. Troner, C. L. Vogel

Research output: Contribution to journalArticle

23 Scopus citations

Abstract

The combination of mitomycin C and vinblastine in the dose and schedule used in this study (6 and 5 mg/m2, respectively, every 14 days) was of little clinical efficacy in the management of metastatic breast cancer already refractory to standard chemotherapy and hormonal therapeutic approaches.

Original languageEnglish (US)
Pages (from-to)2113-2115
Number of pages3
JournalCancer Treatment Reports
Volume62
Issue number12
StatePublished - Dec 1 1978

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II study of mitomycin C and vinblastine in women with advanced breast cancer refractory to standard cytotoxic therapy'. Together they form a unique fingerprint.

  • Cite this